CA2922901A1 - Methodes de traitement du syndrome de l'x fragile et de troubles associes - Google Patents

Methodes de traitement du syndrome de l'x fragile et de troubles associes Download PDF

Info

Publication number
CA2922901A1
CA2922901A1 CA2922901A CA2922901A CA2922901A1 CA 2922901 A1 CA2922901 A1 CA 2922901A1 CA 2922901 A CA2922901 A CA 2922901A CA 2922901 A CA2922901 A CA 2922901A CA 2922901 A1 CA2922901 A1 CA 2922901A1
Authority
CA
Canada
Prior art keywords
metadoxine
mice
treatment
administration
treated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2922901A
Other languages
English (en)
Inventor
Yaron DANIELY
Dalia Megiddo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arcturus Therapeutics Ltd
Original Assignee
Alcobra Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/038,258 external-priority patent/US20150073023A1/en
Application filed by Alcobra Ltd filed Critical Alcobra Ltd
Publication of CA2922901A1 publication Critical patent/CA2922901A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
CA2922901A 2013-09-09 2014-09-09 Methodes de traitement du syndrome de l'x fragile et de troubles associes Abandoned CA2922901A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361875384P 2013-09-09 2013-09-09
US61/875,384 2013-09-09
US14/038,258 2013-09-26
US14/038,258 US20150073023A1 (en) 2013-09-09 2013-09-26 Method Of Treating Fragile X Syndrome And Related Disorders
US201461991351P 2014-05-09 2014-05-09
US61/991,351 2014-05-09
PCT/IB2014/002398 WO2015033224A2 (fr) 2013-09-09 2014-09-09 Méthodes de traitement du syndrome de l'x fragile et de troubles associés

Publications (1)

Publication Number Publication Date
CA2922901A1 true CA2922901A1 (fr) 2015-03-12

Family

ID=52629036

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2922901A Abandoned CA2922901A1 (fr) 2013-09-09 2014-09-09 Methodes de traitement du syndrome de l'x fragile et de troubles associes
CA2923421A Abandoned CA2923421A1 (fr) 2013-09-09 2014-09-09 Procedes de determination d'une reponse a un traitement

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2923421A Abandoned CA2923421A1 (fr) 2013-09-09 2014-09-09 Procedes de determination d'une reponse a un traitement

Country Status (12)

Country Link
EP (2) EP3044589A1 (fr)
JP (2) JP2016530536A (fr)
KR (2) KR20160078956A (fr)
CN (2) CN105917225A (fr)
AU (2) AU2014315026A1 (fr)
CA (2) CA2922901A1 (fr)
EA (2) EA201690559A1 (fr)
IL (2) IL244343A0 (fr)
MX (2) MX2016003002A (fr)
SG (2) SG11201601830PA (fr)
TW (2) TW201605443A (fr)
WO (2) WO2015035402A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3239161A1 (fr) * 2013-07-31 2017-11-01 UDC Ireland Limited Complexes de carbène-métal diazabenzimidazole luminescent
US20150073023A1 (en) 2013-09-09 2015-03-12 Alcobra Ltd. Method Of Treating Fragile X Syndrome And Related Disorders
CN108538365A (zh) * 2017-03-24 2018-09-14 华东师范大学 一种基于数据分析技术的自闭症社交能力评估系统
JP2021524836A (ja) * 2018-04-13 2021-09-16 ヒールクス リミテッドＨｅａｌｘ Ｌｉｍｉｔｅｄ 脆弱ｘ症候群の治療
KR20190121569A (ko) * 2018-04-18 2019-10-28 건국대학교 글로컬산학협력단 아그마틴 및 이의 약학적으로 허용 가능한 염을 포함하는 취약 x 증후군 예방 또는 치료용 약학조성물
EP3813816B1 (fr) * 2018-06-07 2023-06-07 Ovid Therapeutics Inc. Utilisation de l'acide (s)-3-amino-4-(difluorométhylényl)cyclopent-1-ène-1-carboxylique et de composés apparentés, de l'acide (1s,3s)-3-amino-4-(difluorométhylidène)cyclopentane-1-carboxylique dans le traitement de le syndrome de l'x fragile ou le syndrome de tremblement/ataxie associé à l'x fragile
JP2023523119A (ja) * 2020-01-08 2023-06-02 ニューロヴェンティ カンパニー リミテッド リスリド化合物を有効成分として含む脆弱ｘ症候群または関連発達障害治療用組成物
EP4101448A4 (fr) * 2020-02-07 2024-04-24 Neuroventi Composition comprenant un composé de rilmenidine en tant que principe actif pour le traitement du syndrome de l'x fragile ou de la déficience développementale associée

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1131856B (it) 1980-06-30 1986-06-25 Baldacci Lab Spa Composizione farmaceutica per il trattamento di intossicazioni alcooliche
WO2002043507A2 (fr) * 2000-11-30 2002-06-06 The Health Research Institute Complements nutritifs et procedes de traitement de l'autisme et de prevention de l'apparition de l'autisme
IL187159A0 (en) 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
NZ597319A (en) * 2009-06-25 2014-06-27 Alcobra Ltd A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition

Also Published As

Publication number Publication date
KR20160086818A (ko) 2016-07-20
MX2016003002A (es) 2016-09-08
JP2016530291A (ja) 2016-09-29
SG11201601830PA (en) 2016-04-28
CA2923421A1 (fr) 2015-03-12
TW201606304A (zh) 2016-02-16
EA201690557A1 (ru) 2016-07-29
EA201690559A1 (ru) 2016-08-31
CN105917225A (zh) 2016-08-31
AU2014316779A1 (en) 2016-03-17
WO2015035402A1 (fr) 2015-03-12
MX2016003006A (es) 2016-06-10
JP2016530536A (ja) 2016-09-29
IL244343A0 (en) 2016-04-21
KR20160078956A (ko) 2016-07-05
TW201605443A (zh) 2016-02-16
SG11201601605YA (en) 2016-04-28
EP3044589A1 (fr) 2016-07-20
WO2015033224A2 (fr) 2015-03-12
EP3043792A2 (fr) 2016-07-20
IL244453A0 (en) 2016-04-21
AU2014315026A1 (en) 2016-03-24
WO2015033224A3 (fr) 2015-07-02
CN105517546A (zh) 2016-04-20

Similar Documents

Publication Publication Date Title
CA2922901A1 (fr) Methodes de traitement du syndrome de l'x fragile et de troubles associes
CA2580619C (fr) Utilisation de memantine (namenda) pour traiter l'autisme, les etats compulsifs et impulsifs
JP5875191B2 (ja) Ｃｍｔ及び関連障害を処置するための新たな組成物
US11690812B2 (en) Methods and compositions for the treatment of steatosis-associated disorders
EA024465B1 (ru) ПРИМЕНЕНИЕ ЛЕВОСИМЕНДАНА ИЛИ ЕГО СОЛЕЙ ДЛЯ ПРИГОТОВЛЕНИЯ МЕДИКАМЕНТА ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА И РОДСТВЕННЫХ РАССТРОЙСТВ ИЛИ ДЛЯ ЗАЩИТЫ ЭНДОТЕЛИАЛЬНЫХ И/ИЛИ НЕРВНЫХ КЛЕТОК ОТ Аβ ТОКСИЧНОСТИ И СПОСОБ ЛЕЧЕНИЯ УКАЗАННЫХ ЗАБОЛЕВАНИЙ
JP2007517040A (ja) 睡眠の質を改善するためのメラトニン併用療法
JP2010504338A (ja) 筋萎縮性側索硬化症（ＡＬＳ）の治療のための水素化ピリド［４，３−ｂ］インドール
WO2005063248A1 (fr) Therapie combinatoire avec la modafinile pour ameliorer la qualite du sommeil
CZ6498A3 (cs) Použití rapamycinu a jeho derivátů v kombinaci s antagonistou NMDA a/nebo AMPA pro výrobu farmaceutických prostředků
EP3193907B1 (fr) Procédé de traitement de syndrome prader-willi
US11278531B2 (en) Combination of ibudilast and riluzole and methods of using same
Nociari et al. Lipofuscin accumulation into and clearance from retinal pigment epithelium lysosomes: Physiopathology and emerging therapeutics
US9851354B2 (en) Methods of treating fragile X syndrome and related disorders
US20210330611A1 (en) Therapy for neurological diseases/disorders
IL298334A (en) A canceled gaboxadol ring and its use for the treatment of psychiatric disorders
US20180318243A1 (en) Use of lithium benzoate for treating central nervous system disorders
US20220105106A1 (en) Compositions and methods relating to use of agonists of alpha5-containing gabaa receptors
JP2019511495A (ja) ＧＳＫ３β阻害薬チデグルシブによるＣＤＫＬ５障害の治療
CN114072154A (zh) 用于治疗精神障碍的加波沙朵和锂的组合物
EP3661492A1 (fr) Procédés et compositions pour traiter des troubles neurologiques
EP4252748A1 (fr) Modulateur du récepteur de sphingosine-1-phosphate (s1pr) destiné à être utilisé dans le traitement d'un patient souffrant de démence d'alzheimer
CN117479931A (zh) 用于治疗孤独症谱系障碍(asd)的方法
US20110268717A1 (en) Herbal-Based Compositions for Alleviating Symptoms Associated with Autism
US20150366847A1 (en) Combination of geranylgeranylacetone and ibudilast and methods of using same
US20150320705A1 (en) Method of inhibiting or treating amyotrophic lateral sclerosis with phenoxyalkylcarboxylic acids

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180911